Development and License Agreements - Additional Information (Detail) € in Millions	1 Months Ended			12 Months Ended
	Sep. 30, 2020 USD ($)	Aug. 31, 2019 USD ($)	Aug. 31, 2019 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Apr. 30, 2020 USD ($)
Licenses Agreements [Line Items]
Payments made relating to the manufacturing of the products				$ 31,300,000		$ 29,500,000	$ 21,300,000
BARDA Agreement
Licenses Agreements [Line Items]
Additional committed fund receivable										$ 13,800,000
Committed fund receivable				116,900,000
Committed fund receivable				213,900,000
Accounts receivable of billed and unbilled amounts				4,600,000		$ 4,200,000
FDA Agreement
Licenses Agreements [Line Items]
Contract agreement term	5 years
Total potential contract value	$ 11,100,000
FDA Agreement | Maximum
Licenses Agreements [Line Items]
Accounts receivable of billed and unbilled amounts				100,000
Cerus Corporation | BARDA Agreement
Licenses Agreements [Line Items]
Co-investment by the company				5,000,000.0
Additional co-investment by the company				9,600,000
Co-investment incurred by the company				$ 2,200,000
Manufacturing and Supply Agreement | Fresenius
Licenses Agreements [Line Items]
Payments made based on the successful achievement of production volumes | €					€ 8.6
Manufacturing and development payments		$ 6,200,000	€ 5.5					$ 3,400,000	€ 3.1